{"entity":{"id":"nct07586202","kind":"trial","name":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC","aka":["AmiNA"],"tldr":"A phase 2 trial of Amivantamab, Lazertinib, Carboplatin and Pemetrexed in non-small-cell lung cancer, run by Janssen Research & Development, LLC, now recruiting.","summary":"A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC is a phase 2 interventional study registered as NCT07586202 by Janssen Research & Development, LLC, with 68 participants planned, started 2026-07-28 and due to reach its primary completion in 2028-03-02. Interventions recorded: Amivantamab, Lazertinib, Carboplatin and Pemetrexed.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07586202","url":"https://clinicaltrials.gov/study/NCT07586202"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc","egfr-mutant-nsclc","resectable-nsclc"],"sections":[],"technologies":["bispecific-antibody","kinase-inhibitors"],"targets":[],"drugs":["amivantamab","lazertinib","carboplatin","pemetrexed"],"companies":["johnson-johnson"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT07586202","phase":"2","setting":"A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination With Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer","sponsor":"Janssen Research & Development, LLC","participation":[{"nct":"NCT07586202","source":"https://clinicaltrials.gov/study/NCT07586202","fetchedAt":"2026-10-07T16:55:50.238Z","studySha256":"274928805a23310386cd6caeccea98fa72ef402ddb48f608dba84eae5b21fc6a","overallStatus":"RECRUITING","lastUpdatePosted":"2026-09-25","leadSponsor":"Janssen Research & Development, LLC","collaboratorCount":0,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":68,"enrolmentType":"ESTIMATED","siteCount":23,"recruitingSiteCount":23,"countries":["Canada","China","South Korea","Spain","Taiwan","United States"]}],"started":"2026-07-28","startedType":"actual","enrolled":68,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07586202/","neighbours":{"cancer":[{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"resectable-nsclc","kind":"cancer","name":"Resectable stage I to III non-small-cell lung cancer","route":"/cancers/resectable-nsclc/"}],"technology":[{"id":"bispecific-antibody","kind":"technology","name":"Bispecific antibodies","route":"/technologies/bispecific-antibody/"},{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"drug":[{"id":"amivantamab","kind":"drug","name":"Amivantamab","route":"/drugs/amivantamab/"},{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"lazertinib","kind":"drug","name":"Lazertinib","route":"/drugs/lazertinib/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/"}]}}